MAPT and Alzheimer disease: Moreover, research suggests a potential link between genetic risk factors, AD-related changes, and the co-occurrence of TDP-43 and tau in FTLD, which could indirectly influence clinical presentation, especially if AD pathology contributes to cognitive decline [60].